A Retrospective Analysis of Outcomes of Diffuse Large B Cell Lymphoma (DLBCL) in the Elder Patients in China
Peng Liu(Jiangxi University of Traditional Chinese Medicine), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan Sun(Peking University), Liqiang Zhou(Henan University of Science and Technology), Ying Han(Fujian University of Traditional Chinese Medicine), Xiaohui He(Chinese Academy of Medical Sciences & Peking Union Medical College), Shengyu Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Mingzhe Han(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianliang Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Changgong Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 0
Related Papers
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
|The Lancet|2008|1.2k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
In silico ADME and Toxicity Prediction of Ceftazidime and Its Impurities
|Frontiers in Pharmacology|2019|287
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256